{"outcome_uid": "b79389f0", "clinical_question": "Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?", "population": "Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI", "intervention": "Treatment with NOACs or warfarin", "comparator": "No treatment with NOACs or warfarin", "outcome": "Major hemorrhagic event", "importance": "CRITICAL", "related_paper_list": ["39c02ac0"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NONE", "rationales": "Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail."}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study, therefore not possible to assess"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": "Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)"}, "Imprecision": {"result": "SERIOUS", "rationales": "Only data from one study. CI straddles 1.0. Optimal information size (OIS) was not met (control event rate 0.066; total events 144 observed; total events required 220-660 (RRR 20-30 %). Less than 400 events but more than 100. Wide confidence intervals."}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "Risk": {"No treatment (comparator) mean (SD)": {"39c02ac0": "66/1000"}, "Treatment with anticoagulants (intervention) mean (SD)": {"39c02ac0": "76/1000"}}, "Effect": {"Mean difference": {"39c02ac0": "1.07 (0.82 - 1.39) (Hazard ratio (95 % confidence interval))"}}}}, "PICO_IDX": "2a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "664e86e1", "clinical_question": "Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?", "population": "Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI", "intervention": "Treatment with NOACs or warfarin", "comparator": "No treatment with NOACs or warfarin", "outcome": "Mortality", "importance": "IMPORTANT", "related_paper_list": ["39c02ac0"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NONE", "rationales": "Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail."}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study, therefore not possible to assess"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": "Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)"}, "Imprecision": {"result": "SERIOUS", "rationales": "Only data from one study. CI straddles 1.0. Optimal information size (OIS) was met (control event rate 0.364; total events 630 observed; total events required 200-450 (RRR 20-30 %). Wide confidence intervals"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "Risk": {"No treatment (comparator) mean (SD)": {"39c02ac0": "364/1000"}, "Treatment with anticoagulants (intervention) mean (SD)": {"39c02ac0": "266/1000"}}, "Effect": {"Mean difference": {"39c02ac0": "0.88 (0.77 - 1.01) (Hazard ratio (95 % confidence interval))"}}}}, "PICO_IDX": "2a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "ba86aefa", "clinical_question": "Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?", "population": "Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI", "intervention": "Treatment with NOACs or warfarin", "comparator": "No treatment with NOACs or warfarin", "outcome": "Ischemic stroke", "importance": "CRITICAL", "related_paper_list": ["39c02ac0"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NONE", "rationales": "Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail."}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study, therefore not possible to assess"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": "Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)"}, "Imprecision": {"result": "SERIOUS", "rationales": "Only data from one study. CI straddles 1.0. Optimal information size (OIS) was not met (control event rate 0.053; total events 95 observed; total events required 230-670 (RRR 20-30 %). Less than 100 events."}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Observational Study", "Certainty": "VERY LOW", "Risk": {"No treatment (comparator) mean (SD)": {"39c02ac0": "53/1000"}, "Treatment with anticoagulants (intervention) mean (SD)": {"39c02ac0": "42/1000"}}, "Effect": {"Mean difference": {"39c02ac0": "0.74 (0.54 - 1.03) (Hazard ratio (95 % confidence interval))"}}}}, "PICO_IDX": "2a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "c463b84c", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": " No pharmacological treatment ", "outcome": "Mortality", "importance": "CRITICAL", "related_paper_list": ["50df60b4", "f5076959", "0643f463", "44c2f905", "d21566cc"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, few patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"No treatment (comparator) mean change score (SD) OR n/N": {"50df60b4": "3.3% (placebo)", "f5076959": "0/46", "0643f463": "3/139", "44c2f905": "0/31", "d21566cc": "4/166"}, "Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N": {"50df60b4": "5.1% (quetiapine 200 mg/day), 7.3% (queti- apine 100 mg/day)", "f5076959": "0/160", "0643f463": "5/274", "44c2f905": "1/30", "d21566cc": "6/161"}}, "Effect": {"Mean difference in change score OR Relative risk (95 % CI)": {"50df60b4": "RR 2.08 (95% CI: 0.61 - 7.16) (RR and percentage mortality includes 30-day follow-up. Nine Deaths occurred during the trial and 10 in the 30-day follow-up period)", "f5076959": "NA (Due to no events in one or both arms RR cannot be calculated)", "0643f463": "RR 0.85 (95% CI: 0.21 to 3.50)", "44c2f905": "NA (Due to no events in one or both arms RR cannot be calculated)", "d21566cc": "RR 1.53 (95% CI: 0.44 - 5.31)"}}}}, "PICO_IDX": "4a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "e0b56f32", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": " No pharmacological treatment ", "outcome": "Agitation/aggression", "importance": "IMPORTANT", "related_paper_list": ["50df60b4", "f5076959", "c6e3bcaf", "44c2f905", "d21566cc"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Point estimates vary widely, the direction of the effect is not consistent between the included studies"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Wide confidence intervals, few patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"No treatment (comparator) mean change score (SD) OR n/N": {"50df60b4": "-2.5 (SD 0.9)", "f5076959": "-2.1 (SD 4.6)", "c6e3bcaf": "-0.1 (1.0)", "44c2f905": "-9.0 (16.5)", "d21566cc": "-3.1"}, "Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N": {"50df60b4": "Intervention 1: - 2.5 (0.9); intervention 2: -1.8 (0.8)", "f5076959": "Intervention 1: -4.1 (3.7) Intervention 2: -3.9 (4.2) Intervention 3: -3.1 (4.1) ", "c6e3bcaf": "Intervention 1: -0.4 (2.1) Intervention 2: -0.3 (1.0) Intervention 3: -0.2 (1.1) ", "44c2f905": "-8.1 (12.7)", "d21566cc": "-7.5"}}, "Effect": {"Mean difference in change score OR Relative risk (95 % CI)": {"50df60b4": "Intervention 1: 0 (95% CI: -0.25 to 0.25); Intervention 2 (95% CI 0.46 to 0.94)", "f5076959": "Intervention 1: -2 (95% CI -3.53 - 0.48); Intervention 2: -1.8, (95% CI -3.48 to 0.13); Intervention 3: -1 (95% CI 2.63 to -0.63,)", "c6e3bcaf": "Intervention 1: -0.3 (95% CI -0.70 to 0.10,); Intervention 2: -0.2 (95% CI -0.46 to 0.06); Intervnetion 3: - 0.1 (95% CI -0.38 to 0.18)", "44c2f905": "0.9 (95% CI -6.58 to 8.38)", "d21566cc": "-4.4 (SD not reported for change scores)"}}}}, "PICO_IDX": "4a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "9fbb3c56", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": " No pharmacological treatment ", "outcome": "Global cognitive function", "importance": "IMPORTANT", "related_paper_list": ["baf84590", "f5076959", "c6e3bcaf", "44c2f905"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Few patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "Risk": {"No treatment (comparator) mean change score (SD) OR n/N": {"baf84590": "Not reported", "f5076959": "-0.3 (2.2) ", "c6e3bcaf": "-0.7 (2.7) ", "44c2f905": "3.3 (17.4) "}, "Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N": {"baf84590": "Not reported", "f5076959": "Intervention 1: -0.5 (3.3); Intervention 2: -1 (3.1); Intervention 3: -0.3 (2.2) ", "c6e3bcaf": "Intervention 1: -0.1 (3.7); Intervention 2: -0.8 (3.8); Intervention 3: -0.8 (3.2)", "44c2f905": "-11.3 (15.6)"}}, "Effect": {"Mean difference in change score OR Relative risk (95 % CI)": {"baf84590": "-0.1 (-2.9 to 2.6)", "f5076959": "Intervention 1: -0.2, (95% CI -0.92 to 1.32); Intervention 2: -0.7 (95% CI -0.39 to 1.79); Intervention 3: 0 (95% CI -0.88 to 0.88)", "c6e3bcaf": "Intervention 1: 0.6 (95% CI -0.21 to 1.41); Intervention 2: -0.1 (95% CI -0.93 to 0.73); Intervention 3: -0.1 (95% CI -0.88 to 0.68)", "44c2f905": "−15.4 (−27.0 to −3.8)"}}}}, "PICO_IDX": "4a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "5920def2", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": " No pharmacological treatment ", "outcome": "SAEs", "importance": "CRITICAL", "related_paper_list": ["50df60b4", "baf84590", "0643f463", "44c2f905", "d21566cc"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, few patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"No treatment (comparator) mean change score (SD) OR n/N": {"50df60b4": "9/83", "baf84590": "2/18", "0643f463": "19/123", "44c2f905": "1/30 ", "d21566cc": "15/155"}, "Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N": {"50df60b4": "21/220", "baf84590": "2/18", "0643f463": "40/239", "44c2f905": "1/30", "d21566cc": "28/139"}}, "Effect": {"Mean difference  in change score OR Relative risk (95 % CI)": {"50df60b4": "RR: 0.89 (95% CI: 0.42 to 1.87)", "baf84590": "RR: 1 (95% CI: 0.16 to 6.42)", "0643f463": "RR: 1.07 (95% CI: 0.65 to 1.78)", "44c2f905": "RR: 1 (95% CI: 0.07 to 15.28)", "d21566cc": "RR: 1.9 (95% CI: 1.05 to 3.43)"}}}}, "PICO_IDX": "4a", "Database": "2020 EAN Dementia"}
{"outcome_uid": "b36ddbfc", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": "Haloperidol", "outcome": "Mortality", "importance": "CRITICAL", "related_paper_list": ["2271541c", "793447a7", "8c317dba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Low number of patients, no events in any studies"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"Treatment with haloperidol (comparator) mean change score OR n/N": {"2271541c": "0/60", "793447a7": "0/28", "8c317dba": "0/29"}, "Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N": {"2271541c": "0/60", "793447a7": "0/30", "8c317dba": "0/29"}}, "Effect": {"Mean difference  in change score OR Relative risk (95 % CI)": {"2271541c": "NA (Due to no events in one or both arms RR cannot be calculated)", "793447a7": "NA (Due to no events in one or both arms RR cannot be calculated)", "8c317dba": "NA (Due to no events in one or both arms RR cannot be calculated)"}}}}, "PICO_IDX": "4b", "Database": "2020 EAN Dementia"}
{"outcome_uid": "19c9b59e", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": "Haloperidol", "outcome": "Agitation/aggression", "importance": "IMPORTANT", "related_paper_list": ["2271541c", "793447a7", "8c317dba", "64979d7f"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Point estimates vary widely"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Few patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"Treatment with haloperidol (comparator) mean change score OR n/N": {"2271541c": "4.9", "793447a7": "-16.6", "8c317dba": "-10", "64979d7f": "-3.6"}, "Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N": {"2271541c": "-11.2", "793447a7": "-10.1(-18.6 to - 1.5)", "8c317dba": "-8.1", "64979d7f": "-8.3"}}, "Effect": {"Mean difference  in change score OR Relative risk (95 % CI)": {"2271541c": "-6.3 (SD or other measure of variance not reported. Scores are mean change scores)", "793447a7": "6.5", "8c317dba": "1.9 (SD or other measure of variance not reported. Scores are mean change scores)", "64979d7f": "-4.7 (SD or other measure of variance not reported. Scores are mean change scores)"}}}}, "PICO_IDX": "4b", "Database": "2020 EAN Dementia"}
{"outcome_uid": "9394e2f2", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": "Haloperidol", "outcome": "Global cognitive function", "importance": "IMPORTANT", "related_paper_list": ["793447a7", "8c317dba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Point estimates vary widely "}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Low number of patients"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"Treatment with haloperidol (comparator) mean change score OR n/N": {"793447a7": "-0.13", "8c317dba": "-0.15"}, "Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N": {"793447a7": "0.53", "8c317dba": "-0.42"}}, "Effect": {"Mean difference  in change score OR Relative risk (95 % CI)": {"793447a7": "0.66 (SD not reported. Values are for change from baseline)", "8c317dba": "-0.27 (SD not reported. Values are for change from baseline)"}}}}, "PICO_IDX": "4b", "Database": "2020 EAN Dementia"}
{"outcome_uid": "c44985bf", "clinical_question": "Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?", "population": "Patients with dementia and agitation/aggressive behavior ", "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine", "comparator": "Haloperidol", "outcome": "Serious adverse events", "importance": "CRITICAL", "related_paper_list": ["2271541c"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Due to no events in one or both arms RR cannot be calculated"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Only data from one study. Low number of patients, no events in the study"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"Treatment with haloperidol (comparator) mean change score OR n/N": {"2271541c": "0/60"}, "Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N": {"2271541c": "0/60"}}, "Effect": {"Mean difference  in change score OR Relative risk (95 % CI)": {"2271541c": "N/A (Due to no events in one or both arms RR cannot be calculated)"}}}}, "PICO_IDX": "4b", "Database": "2020 EAN Dementia"}
{"outcome_uid": "d9b623af", "clinical_question": "Should treatment with antipsychotics be routinely discontinued?", "population": "Patients dementia who are currently being treated with anti-psychotics", "intervention": "Discontinuation of antipsychotics", "comparator": "Continuation of treatment", "outcome": "Mortality", "importance": "CRITICAL", "related_paper_list": ["39351825", "7e48dccc", "8f835918", "c57b6880", "135b5748", "aead9e3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, Low number of patients, few events in any studies"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N": {"39351825": "1/27", "7e48dccc": " 0/14", "8f835918": "1/69", "c57b6880": "3/51", "135b5748": "10/72", "aead9e3a": "0/10"}, "Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N": {"39351825": "3/24", "7e48dccc": "0/22", "8f835918": "1/39", "c57b6880": "3/43", "135b5748": "2/83", "aead9e3a": "0/10"}}, "Effect": {"Mean difference (95 % CI) OR Relative risk (95 % CI)": {"39351825": "3.11 (0.34 - 28.09)", "7e48dccc": "NA (Due to no events in one or both arms RR cannot be calculated)", "8f835918": "1.75", "c57b6880": "1.17 (0.25 - 5.54)", "135b5748": "0.19 (0.046 to 0.90)", "aead9e3a": "NA (Due to no events in one or both arms RR cannot be calculated)"}}}}, "PICO_IDX": "4c", "Database": "2020 EAN Dementia"}
{"outcome_uid": "401a51cf", "clinical_question": "Should treatment with antipsychotics be routinely discontinued?", "population": "Patients dementia who are currently being treated with anti-psychotics", "intervention": "Discontinuation of antipsychotics", "comparator": "Continuation of treatment", "outcome": "Neuropsychiatric symptoms", "importance": "IMPORTANT", "related_paper_list": ["39351825", "1ad70ba1", "c57b6880", "4f4e0f75", "aead9e3a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, Low number of patients, low number of events"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "Risk": {"Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N": {"39351825": "-1.79 (4.9)", "1ad70ba1": "Results only reported in a figure. No measure of variance.", "c57b6880": "0.2 (12) ", "4f4e0f75": "3.52 (20.78) ", "aead9e3a": "N/A"}, "Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N": {"39351825": "-0.19 (5.3)", "1ad70ba1": "N/A", "c57b6880": "-1.3 (9.4)", "4f4e0f75": " 2.04 (18.2)", "aead9e3a": "N/A"}}, "Effect": {"Mean difference (95 % CI) OR Relative risk (95 % CI)": {"39351825": "1.6 (95% CI   -1.16 to 4.36)", "1ad70ba1": "N/A", "c57b6880": "-1.5 (95% CI -6.34 to -3.34)", "4f4e0f75": "-1.48 (-8.70 to 5.74)", "aead9e3a": "1.94; (1.09 to -3.45) (Hazard ratios for the first 16 weeks of phase B. Hazard ratio for placebo compared to antipsychotics)"}}}}, "PICO_IDX": "4c", "Database": "2020 EAN Dementia"}
{"outcome_uid": "ddb1d46f", "clinical_question": "Should treatment with antipsychotics be routinely discontinued?", "population": "Patients dementia who are currently being treated with anti-psychotics", "intervention": "Discontinuation of antipsychotics", "comparator": "Continuation of treatment", "outcome": "Global cognitive function", "importance": "IMPORTANT", "related_paper_list": ["4f4e0f75"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, Low number of patients, Only data from one study"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N": {"4f4e0f75": "-16.5 (23.1)"}, "Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N": {"4f4e0f75": "-8.5 (13.4)"}}, "Effect": {"Mean difference (95 % CI) OR Relative risk (95 % CI)": {"4f4e0f75": "8 (2.20 - 13.80) (Calculated)"}}}}, "PICO_IDX": "4c", "Database": "2020 EAN Dementia"}
{"outcome_uid": "4af0eee8", "clinical_question": "Should treatment with antipsychotics be routinely discontinued?", "population": "Patients dementia who are currently being treated with anti-psychotics", "intervention": "Discontinuation of antipsychotics", "comparator": "Continuation of treatment", "outcome": "Serious adverse events", "importance": "CRITICAL", "related_paper_list": ["8f835918"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study"}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide confidence intervals, Low number of patients, Only data from one study, low number of events"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N": {"8f835918": "5/65"}, "Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N": {"8f835918": "8/32"}}, "Effect": {"Mean difference (95 % CI) OR Relative risk (95 % CI)": {"8f835918": "2.80 (0.98 - 7.98)"}}}}, "PICO_IDX": "4c", "Database": "2020 EAN Dementia"}
{"outcome_uid": "e7e8c033", "clinical_question": "Should behavioral symptoms in patients with dementia be treated with mild analgesics?", "population": "Patients with dementia and behavioral symptoms", "intervention": "Treatment with mild analgesics (paracetamol)", "comparator": " No treatment with analgesics ", "outcome": "Agitation/aggression", "importance": "CRITICAL", "related_paper_list": ["0e34e33b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study, therefore not possible to assess"}, "Indirectness": {"result": "SERIOUS", "rationales": "Patients were not included based on having behavioural symptoms. No baseline data related to assessment of behavioural symptoms were reported."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "to wide CIs, few patients, one study"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"No treatment (comparator) mean (SD)": {"0e34e33b": "1.6 (0.5) (Mean score at follow-up on the Cohen-Mansfield Agitation Inventory)"}, "Treatment with mild analgesics (intervention) mean (SD)": {"0e34e33b": "1.6 (0.5) (Mean score at follow-up on the Cohen-Mansfield Agitation Inventory)"}}, "Effect": {"Mean difference": {"0e34e33b": "0"}}}}, "PICO_IDX": "5b", "Database": "2020 EAN Dementia"}
{"outcome_uid": "5af071df", "clinical_question": "Should behavioral symptoms in patients with dementia be treated with mild analgesics?", "population": "Patients with dementia and behavioral symptoms", "intervention": "Treatment with mild analgesics (paracetamol)", "comparator": " No treatment with analgesics ", "outcome": "Psychotropic treatments", "importance": "IMPORTANT", "related_paper_list": ["0e34e33b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_APPLICABLE", "rationales": "Only one study, therefore not possible to assess"}, "Indirectness": {"result": "SERIOUS", "rationales": "Patients were not included based on having behavioural symptoms. No baseline data related to assessment of behavioural symptoms were reported."}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "to wide CIs, few patients, one study"}, "Publication bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "Risk": {"No treatment (comparator) mean (SD)": {"0e34e33b": "0.8 (1.91)"}, "Treatment with psychotropic treatments (intervention) mean (SD)": {"0e34e33b": "0.52 (1.39)"}}, "Effect": {"Mean difference": {"0e34e33b": "0.28 fewer (MD) (CI 95% 1 fewer - 0.45 more)"}}}}, "PICO_IDX": "5b", "Database": "2020 EAN Dementia"}
